Overview
GRIN2A developmental and epileptic encephalopathy is a genetic disorder characterized by severe intellectual disability, early-onset epilepsy, and developmental regression, often linked to de novo mutations in the GRIN2A gene encoding the GluA2 subunit of AMPA-type glutamate receptors 1.Diagnosis
Genetic testing identifying de novo mutations in GRIN2A 1.
Electroencephalography (EEG) showing characteristic epileptiform discharges 1.
Clinical presentation including early-onset seizures, developmental delay, and regression 1.Management
First-line treatments: Antiepileptic drugs (AEDs) such as valproate, levetiracetam, or clobazam 1.
Adjunctive treatments: Consider NMDA receptor antagonists like memantine, though evidence is primarily preclinical 1.
Pharmacological approaches: AMPA receptor antagonists (e.g., NBQX) and NMDA receptor antagonists (e.g., MK-801) have shown promise in reducing excitotoxicity in preclinical models 1.Special Populations
Pediatrics: Management focuses on controlling seizures and supporting developmental milestones with AEDs tailored to pediatric dosing 1.
Comorbidities: No specific guidance provided in the abstracts; management should address comorbid conditions alongside seizure control 1.Key Recommendations
Initiate genetic testing to identify GRIN2A mutations for accurate diagnosis (Evidence: Expert opinion) 1.
Use antiepileptic drugs such as valproate, levetiracetam, or clobazam as first-line therapy for seizure control (Evidence: Expert opinion) 1.
Consider adjunctive therapies targeting glutamate pathways, such as NMDA receptor antagonists, based on preclinical efficacy, though clinical evidence is limited (Evidence: Weak) 1.References
1 Fujisawa H, Dawson D, Browne SE, MacKay KB, Bullock R, McCulloch J. Pharmacological modification of glutamate neurotoxicity in vivo. Brain research 1993. link90483-4)